Cargando…

330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis

BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening disorder resulting from dysregulated cytokine production. The diagnosis of HLH requires five of eight abnormalities: fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, hyperferritinemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Timothy J, Prokesch, Bonnie C, Nagalla, Srikanth, Wysocki, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810758/
http://dx.doi.org/10.1093/ofid/ofz360.403
_version_ 1783462320894115840
author Brown, Timothy J
Prokesch, Bonnie C
Nagalla, Srikanth
Wysocki, Christian
author_facet Brown, Timothy J
Prokesch, Bonnie C
Nagalla, Srikanth
Wysocki, Christian
author_sort Brown, Timothy J
collection PubMed
description BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening disorder resulting from dysregulated cytokine production. The diagnosis of HLH requires five of eight abnormalities: fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, hyperferritinemia, hemophagocytosis on biopsy, low or absent NK cell activity, or elevated soluble CD25. The link between Human Immunodeficiency Virus (HIV) and HLH is incompletely understood; we sought to further define the characteristics and outcomes of this patient population. METHODS: We performed a retrospective study on HLH patients with and without concurrent HIV infection treated at our institution from January 2008 to July 2018. At the time of HLH diagnosis, we extracted data on the HIV status and associated malignancies. The primary outcome was overall survival from time of diagnosis of HLH in patients with HIV vs. those without HIV. Secondary analysis was performed with survival by HIV and malignancy status. Survival was analyzed by Kaplan–Meier curves with hazard ratios calculated using the log-rank test with significance set at P ≤ 0.05. RESULTS: Forty-three patients were included; 11 had HIV at the time of diagnosis of HLH and all met criteria for AIDS at time of inclusion. Patients with HIV who were diagnosed with HLH had similar survival compared with patients without HIV (Hazard ratio for death (HR) 0.87 [95% confidence interval (CI) 0.37–2.904]). All patients with malignancy had a worse survival (HR for death 3.648 [95% CI 1.804–9.169] P = 0.0009), regardless of HIV status. HLH in HIV patients with malignancy resulted in a trend toward worse survival (HR = 3.86 95% CI 1.09–22.60, P = 0.0578) compared with those without malignancy, although the limited number of patients prohibits a definitive conclusion. In HIV-negative patients, the presence of malignancy is associated with worse survival (HR 3.56 [95% CI 1.475–10.11] P = 0.0063). CONCLUSION: In this retrospective, single-institution review of HLH patients, HIV was not associated with worse overall survival compared with patients without HIV. The presence of malignancy resulted in worse survival in the overall population. Further investigation is needed to optimize the care of these patients. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810758
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68107582019-10-28 330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis Brown, Timothy J Prokesch, Bonnie C Nagalla, Srikanth Wysocki, Christian Open Forum Infect Dis Abstracts BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening disorder resulting from dysregulated cytokine production. The diagnosis of HLH requires five of eight abnormalities: fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, hyperferritinemia, hemophagocytosis on biopsy, low or absent NK cell activity, or elevated soluble CD25. The link between Human Immunodeficiency Virus (HIV) and HLH is incompletely understood; we sought to further define the characteristics and outcomes of this patient population. METHODS: We performed a retrospective study on HLH patients with and without concurrent HIV infection treated at our institution from January 2008 to July 2018. At the time of HLH diagnosis, we extracted data on the HIV status and associated malignancies. The primary outcome was overall survival from time of diagnosis of HLH in patients with HIV vs. those without HIV. Secondary analysis was performed with survival by HIV and malignancy status. Survival was analyzed by Kaplan–Meier curves with hazard ratios calculated using the log-rank test with significance set at P ≤ 0.05. RESULTS: Forty-three patients were included; 11 had HIV at the time of diagnosis of HLH and all met criteria for AIDS at time of inclusion. Patients with HIV who were diagnosed with HLH had similar survival compared with patients without HIV (Hazard ratio for death (HR) 0.87 [95% confidence interval (CI) 0.37–2.904]). All patients with malignancy had a worse survival (HR for death 3.648 [95% CI 1.804–9.169] P = 0.0009), regardless of HIV status. HLH in HIV patients with malignancy resulted in a trend toward worse survival (HR = 3.86 95% CI 1.09–22.60, P = 0.0578) compared with those without malignancy, although the limited number of patients prohibits a definitive conclusion. In HIV-negative patients, the presence of malignancy is associated with worse survival (HR 3.56 [95% CI 1.475–10.11] P = 0.0063). CONCLUSION: In this retrospective, single-institution review of HLH patients, HIV was not associated with worse overall survival compared with patients without HIV. The presence of malignancy resulted in worse survival in the overall population. Further investigation is needed to optimize the care of these patients. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810758/ http://dx.doi.org/10.1093/ofid/ofz360.403 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Brown, Timothy J
Prokesch, Bonnie C
Nagalla, Srikanth
Wysocki, Christian
330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis
title 330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis
title_full 330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis
title_fullStr 330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis
title_full_unstemmed 330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis
title_short 330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis
title_sort 330. survival of hiv-positive patients with hemophagocytic lymphohistiocytosis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810758/
http://dx.doi.org/10.1093/ofid/ofz360.403
work_keys_str_mv AT browntimothyj 330survivalofhivpositivepatientswithhemophagocyticlymphohistiocytosis
AT prokeschbonniec 330survivalofhivpositivepatientswithhemophagocyticlymphohistiocytosis
AT nagallasrikanth 330survivalofhivpositivepatientswithhemophagocyticlymphohistiocytosis
AT wysockichristian 330survivalofhivpositivepatientswithhemophagocyticlymphohistiocytosis